Core Viewpoint - Truist has lowered its price target for Boston Scientific Corporation (BSX) from $120 to $95 while maintaining a Buy rating, citing that the stock's recent pullback appears excessive given its current valuation compared to faster-growing peers [1] Financial Performance - Boston Scientific's earnings release on February 4 revealed weaker-than-expected results in its electrophysiology business, which is crucial for the company's growth narrative [2] - Fourth-quarter sales in the electrophysiology segment reached $890 million, missing analysts' expectations of $933 million [2] - The sales of the Watchman device, aimed at preventing strokes in patients with atrial fibrillation, were approximately 1% below forecasts, attributed to softer demand in the US market [3] - For the upcoming year, Boston Scientific projects adjusted earnings per share between $3.43 and $3.49, with the midpoint slightly below Wall Street's expectation of $3.47 [3] - Total revenue for the quarter was $5.29 billion, with adjusted earnings of 80¢ per share, both aligning closely with estimates [3] Future Outlook - The company anticipates organic revenue growth of 10% to 11% by 2026, indicating a slowdown compared to the 15.8% organic growth reported in 2025 [4] - Boston Scientific develops and sells medical devices utilized in various interventional procedures globally [4]

Core Insights - Baron Health Care Fund reported a 5.39% increase in Q3 2025, slightly outperforming the Russell 3000 Health Care Index which gained 5.05% [1] - The fund's performance was impacted by stock selection and negative effects from active sub-industry allocations and cash holdings during a rising market [1] Company Performance - Boston Scientific Corporation (NYSE:BSX) achieved a consolidated revenue of $5.065 billion in Q3 2025, reflecting a 20.3% growth compared to Q3 2024 [4] - The stock of Boston Scientific Corporation rose 15.26% over the last 52 weeks, with a one-month return of 2.81% [2][4] - As of November 3, 2025, Boston Scientific's stock closed at $98.59, with a market capitalization of $146.154 billion [2] Competitive Landscape - Boston Scientific faces increasing competition in the pulsed field ablation (PFA) market from Medtronic, Johnson & Johnson, and Abbott, which have launched competing products [3] - Despite the competitive pressures, Boston Scientific is viewed as a strong compounder with a double-digit earnings per share growth profile and ongoing operating margin expansion [3]